New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 29, 2014
11:37 EDTFTR, VMC, CVC, OTEX, TQNT, EWH, GALT, TEF, EXAS, RPRXHigh option volume stocks
High option volume stocks: RPRX EWH CVC EXAS TQNT VMC TEF OTEX FTR GALT
News For RPRX;EWH;CVC;EXAS;TQNT;VMC;TEF;OTEX;FTR;GALT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 25, 2015
10:03 EDTEWHHigh option volume stocks
High option volume stocks: NVO SXC SONC EXH KRFT WLB ETR LXK APOL EWH
March 24, 2015
14:18 EDTRPRXRepros Therapeutics April volatility elevated at 144
Repros Therapeutics April call option implied volatility is at 144, May is at 108, August is at 107; compared to its 26-week average of 103 according to Track Data, suggesting large near term price movement
13:50 EDTTEFTelefonica to sell O2 U.K. to Hutchison Whampoa for GBP10.25B
Subscribe for More Information
13:02 EDTTEFTelefonica agrees to sell O2 unit to Hutchison for GBP10.25B, Bloomberg reports
05:58 EDTTEFHutchison Whampoa to finalize deal to buy O2, Financial Times reports
Subscribe for More Information
March 23, 2015
06:10 EDTTEFBT Group plans to announce BT Mobile 4G network this week, Telegraph reports
BT Group (BT) is said to be planning to announce the launch of its own 4G network this week, The Telegraph reports. The service, BT Mobile, will initially be offered to the company's 7.6M broadband subscribers and will compete with offerings from O2 (TEF) and Vodafone (VOD). Reference Link
March 20, 2015
10:26 EDTCVCCablevision call activity attributed to takeover speculation
Subscribe for More Information
10:07 EDTCVCHigh option volume stocks
Subscribe for More Information
09:59 EDTCVCCharter may have interest in Cablevision 'at some point,' says Detwiler
Detwiler Fenton believes there is truth to last week's reports of Charter (CHTR) being in talks to acquire Bright House Networks. In addition, the firm says its checks indicate Charter may have interest in buying Suddenlink Communications and Cablevision (CVC) "at some point" as a part of a lager acquisition strategy. Detwiler adds Charter's potential deal strategy assumes Comcast's (CMCSA) bid for Time Warner (TWC) wins regulatory approval. Should the deal not get approved, Detwiler believes Charter will turn its attention back to Time Warner.
09:37 EDTCVCRumor: Cablevision strength attributed to takeover speculation
Subscribe for More Information
March 19, 2015
07:17 EDTVMCStephens to hold a conference
Subscribe for More Information
March 18, 2015
17:14 EDTGALTGalectin submitted request for SPA with clinical protocol for GR-MD-02 trial
"I am pleased with our many accomplishments during 2014 as we continue to advance programs with GR-MD-02 for the treatment of nonalcoholic steatohepatitis, NASH, with advanced fibrosis. We completed a successful Phase 1 clinical trial and announced final data in January 2015 that were supportive of our plans to begin a Phase 2 program with GR-MD-02 in advanced fatty liver disease, or NASH with fibrosis and cirrhosis," said Peter G. Traber, M.D., president, CEO and chief medical officer of Galectin Therapeutics. "As announced last month, we submitted the Phase 2 clinical trial protocol to the U.S. Food and Drug Administration, FDA, to evaluate the safety and efficacy of GR-MD-02 for the treatment of liver fibrosis and resultant portal hypertension in patients with NASH cirrhosis, the primary endpoint being to determine the change in the hepatic venous pressure gradient, HVPG, as compared with placebo. The FDA has indicated that HVPG may serve as a surrogate primary endpoint for NASH cirrhosis. We submitted a request for a Special Protocol Assessment with the clinical protocol for this trial. Additionally, we are planning to conduct a separate, shorter Phase 2 trial in NASH patients with advanced fibrosis. We expect to begin enrolling patients in both trials during the second quarter of 2015."
17:08 EDTGALTGalectin Therapeutics reports FY14 EPS (78c), consensus (77c)
As of December 31, the company had $29.1M of non-restricted cash and cash equivalents available to fund future operations. In January and February of 2015, the company received $4.1M in net proceeds from the issuance of common shares through its At-the-Market stock issuance program. The company believes that cash on hand of $29.7M as of March 13, is sufficient to fund its operations and research and development activities through September 30, 2016.
March 16, 2015
17:13 EDTGALTGalectin Therapeutics files form to delay 10-K
Galectin Therapeutics is unable to file, without unreasonable effort or expense, its Annual Report on Form 10-K for the period ended December 31. Because the company was previously a smaller reporting company, this is the first time the company must obtain an audit of its internal control over financial reporting. As a result, additional time is needed for the company to provide its independent auditors with information necessary to complete the audit of the company’s internal control over financial reporting. The company anticipates that its Form 10-K will be filed within the prescribed extension period in accordance with Rule 12b-25(b).
15:24 EDTCVCCablevision to provide HBO NOW via Optimum Online
Cablevision (CVC) and Time Warner's (TWX) Home Box Office announced that they have reached an agreement to offer standalone streaming service HBO NOW to Optimum Online customers via the internet. Optimum is the first cable provider to partner with HBO to offer the new service, which is expected to launch in April in time for the fifth season of Game of Thrones, the companies said. Cablevision plans to provide pricing and other particulars for HBO NOW in the coming weeks. Terms of the agreement were not disclosed. Apple (AAPL) and Time Warner announced on March 9 that HBO NOW will premier on Apple devices in April.
14:54 EDTRPRXFDA accepting Androxal NDA can be catalyst for Repros, says Brean Capital
Subscribe for More Information
10:07 EDTCVCHigh option volume stocks
Subscribe for More Information
09:28 EDTRPRXRepros Therapeutics reports Q4 EPS (31c), consensus (34c)
Subscribe for More Information
09:16 EDTVMCVulcan Materials files automatic mixed securities shelf
08:03 EDTFTRFrontier Communications unit announces alliance with DistiNow
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use